Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

Oncology Consultations™: The Advancing Role of CAR T-Cell Therapies in Hematologic Malignancies

Release Date: April 30, 2018
Expiration Date: April 30, 2019
Media: Internet - based


Activity Overview

This online activity will feature an overview of chimeric antigen receptor (CAR) T cells, including the mechanism of action, key clinical data, and the future direction of CAR T-cell therapy. The format for this Oncology Consultations™ will include 3 modules in a “fireside chat” format during which clinical evidence will be discussed, along with explanations of implications for physician practice.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

CME Activity Table of Contents

  • Pretest
  • Module 1. Biology Behind CAR T-Cell Therapies
  • Module 2. Crossfire Discussion: Application of CAR T-Cell Data
  • Module 3. What Lies Ahead for CAR T Cells?
  • Posttest

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video Files” will be available for your reference.
  • To receive a CME certificate, participants must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and fellows who treat patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Contrast the mechanism of action of CAR T cells with those of other therapeutic options in the treatment of hematologic malignancies
  2. Summarize recent clinical trial data concerning the application of CAR T-cell strategies in the management of hematologic malignancies
  3. Appraise the potential role of CAR T-cell therapies in evolving treatment paradigms for hematologic malignancy management
  4. Describe appropriate techniques to identify and manage different treatment-related toxicities in the care of patients who receive CAR T-cell therapies

Faculty, Staff, and Planners' Disclosures


Anas Younes, MD
Professor and Chief, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant/Research Support: Novartis, J&J, Curis, Roche, Bristol-Myers Squibb; Other Support – Honoraria for Speaking Engagements: Bayer, Bristol-Myers Squibb, Celgene, Incyte, Janssen, Sanofi, Seattle Genetics, Takeda Millennium, Genentech, Merck


Reiner J. Brentjens, MD, PhD
Director, Cellular Therapeutics
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant/Research Support: Juno Therapeutics; Consultant: Juno Therapeutics

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By